ID   ECD_HUMAN               Reviewed;         644 AA.
AC   O95905; C9JX46; E9PAW8;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   05-FEB-2025, entry version 182.
DE   RecName: Full=Protein ecdysoneless homolog {ECO:0000250|UniProtKB:Q9W032};
DE   AltName: Full=Human suppressor of GCR two {ECO:0000303|PubMed:9928932};
DE            Short=hSGT1 {ECO:0000303|PubMed:9928932};
GN   Name=ECD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Brain;
RX   PubMed=9928932; DOI=10.1007/s004380050926;
RA   Sato T., Jigami Y., Suzuki T., Uemura H.;
RT   "A human gene, hSGT1, can substitute for GCR2, which encodes a general
RT   regulatory factor of glycolytic gene expression in Saccharomyces
RT   cerevisiae.";
RL   Mol. Gen. Genet. 260:535-540(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Signet-ring cell carcinoma;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, INTERACTION WITH TP53 AND MDM2, AND SUBCELLULAR LOCATION.
RX   PubMed=16849563; DOI=10.1158/0008-5472.can-06-0722;
RA   Zhang Y., Chen J., Gurumurthy C.B., Kim J., Bhat I., Gao Q., Dimri G.,
RA   Lee S.W., Band H., Band V.;
RT   "The human orthologue of Drosophila ecdysoneless protein interacts with p53
RT   and regulates its function.";
RL   Cancer Res. 66:7167-7175(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503; SER-505 AND SER-518, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH RB1; RBL1 AND RBL2.
RX   PubMed=19640839; DOI=10.1074/jbc.m109.030551;
RA   Kim J.H., Gurumurthy C.B., Naramura M., Zhang Y., Dudley A.T., Doglio L.,
RA   Band H., Band V.;
RT   "Role of mammalian Ecdysoneless in cell cycle regulation.";
RL   J. Biol. Chem. 284:26402-26410(2009).
RN   [10]
RP   FUNCTION, INTERACTION WITH EP300, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ILE-481; ASP-484; LEU-489; ASP-510; ASP-512 AND ASP-520.
RX   PubMed=19919181; DOI=10.1515/bc.2010.004;
RA   Kim J.H., Gurumurthy C.B., Band H., Band V.;
RT   "Biochemical characterization of human Ecdysoneless reveals a role in
RT   transcriptional regulation.";
RL   Biol. Chem. 391:9-19(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=22270930; DOI=10.1007/s10549-011-1946-8;
RA   Zhao X., Mirza S., Alshareeda A., Zhang Y., Gurumurthy C.B., Bele A.,
RA   Kim J.H., Mohibi S., Goswami M., Lele S.M., West W., Qiu F., Ellis I.O.,
RA   Rakha E.A., Green A.R., Band H., Band V.;
RT   "Overexpression of a novel cell cycle regulator ecdysoneless in breast
RT   cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer
RT   patients.";
RL   Breast Cancer Res. Treat. 134:171-180(2012).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=22977192; DOI=10.1158/1078-0432.ccr-12-1789;
RA   Dey P., Rachagani S., Chakraborty S., Singh P.K., Zhao X., Gurumurthy C.B.,
RA   Anderson J.M., Lele S., Hollingsworth M.A., Band V., Batra S.K.;
RT   "Overexpression of ecdysoneless in pancreatic cancer and its role in
RT   oncogenesis by regulating glycolysis.";
RL   Clin. Cancer Res. 18:6188-6198(2012).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH TXNIP.
RX   PubMed=23880345; DOI=10.1016/j.bbrc.2013.07.036;
RA   Suh H.W., Yun S., Song H., Jung H., Park Y.J., Kim T.D., Yoon S.R.,
RA   Choi I.;
RT   "TXNIP interacts with hEcd to increase p53 stability and activity.";
RL   Biochem. Biophys. Res. Commun. 438:264-269(2013).
RN   [16]
RP   INTERACTION WITH PIH1D1.
RX   PubMed=24656813; DOI=10.1016/j.celrep.2014.03.013;
RA   Horejsi Z., Stach L., Flower T.G., Joshi D., Flynn H., Skehel J.M.,
RA   O'Reilly N.J., Ogrodowicz R.W., Smerdon S.J., Boulton S.J.;
RT   "Phosphorylation-dependent PIH1D1 interactions define substrate specificity
RT   of the R2TP cochaperone complex.";
RL   Cell Rep. 7:19-26(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   FUNCTION.
RX   PubMed=24722212; DOI=10.1371/journal.pgen.1004287;
RA   Claudius A.K., Romani P., Lamkemeyer T., Jindra M., Uhlirova M.;
RT   "Unexpected role of the steroid-deficiency protein ecdysoneless in pre-mRNA
RT   splicing.";
RL   PLoS Genet. 10:E1004287-E1004287(2014).
RN   [19]
RP   PHOSPHORYLATION, SUBCELLULAR LOCATION, INTERACTION WITH RUVBL1, ASSOCIATION
RP   WITH THE R2TP COMPLEX, AND MUTAGENESIS OF SER-503; SER-505; SER-518;
RP   SER-572; SER-579 AND SER-584.
RX   PubMed=26711270; DOI=10.1128/mcb.00594-15;
RA   Mir R.A., Bele A., Mirza S., Srivastava S., Olou A.A., Ammons S.A.,
RA   Kim J.H., Gurumurthy C.B., Qiu F., Band H., Band V.;
RT   "A novel interaction of ecdysoneless (ECD) protein with R2TP complex
RT   component RUVBL1 is required for the functional role of ECD in cell cycle
RT   progression.";
RL   Mol. Cell. Biol. 36:886-899(2015).
RN   [20]
RP   FUNCTION, INTERACTION WITH DDX41, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PRO-617.
RX   PubMed=33941617; DOI=10.1128/mcb.00103-21;
RA   Saleem I., Mirza S., Sarkar A., Raza M., Mohapatra B., Mushtaq I.,
RA   Kim J.H., Mishra N.K., Alsaleem M.A., Rakha E.A., Qiu F., Guda C., Band H.,
RA   Band V.;
RT   "The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To
RT   Regulate Nuclear mRNA Export.";
RL   Mol. Cell. Biol. 41:e0010321-e0010321(2021).
RN   [21]
RP   VARIANT GLY-281.
RX   PubMed=11090341; DOI=10.1086/316954;
RA   Bork J.M., Peters L.M., Riazuddin S., Bernstein S.L., Ahmed Z.M.,
RA   Ness S.L., Polomeno R., Ramesh A., Schloss M., Srisailpathy C.R.S.,
RA   Wayne S., Bellman S., Desmukh D., Ahmed Z., Khan S.N., Kaloustian V.M.D.,
RA   Li X.C., Lalwani A., Riazuddin S., Bitner-Glindzicz M., Nance W.E.,
RA   Liu X.-Z., Wistow G., Smith R.J.H., Griffith A.J., Wilcox E.R.,
RA   Friedman T.B., Morell R.J.;
RT   "Usher syndrome 1D and nonsyndromic autosomal recessive deafness DFNB12 are
RT   caused by allelic mutations of the novel cadherin-like gene CDH23.";
RL   Am. J. Hum. Genet. 68:26-37(2001).
CC   -!- FUNCTION: Regulator of p53/TP53 stability and function. Inhibits MDM2-
CC       mediated degradation of p53/TP53 possibly by cooperating in part with
CC       TXNIP (PubMed:16849563, PubMed:23880345). May be involved
CC       transcriptional regulation. In vitro has intrinsic transactivation
CC       activity enhanced by EP300. May be a transcriptional activator required
CC       for the expression of glycolytic genes (PubMed:19919181,
CC       PubMed:9928932). Involved in regulation of cell cycle progression.
CC       Proposed to disrupt Rb-E2F binding leading to transcriptional
CC       activation of E2F proteins (PubMed:19640839). The cell cycle
CC       -regulating function may depend on its RUVBL1-mediated association with
CC       the R2TP complex (PubMed:26711270). May play a role in regulation of
CC       pre-mRNA splicing (PubMed:24722212). Participates together with DDX39A
CC       in mRNA nuclear export (PubMed:33941617). {ECO:0000269|PubMed:16849563,
CC       ECO:0000269|PubMed:19640839, ECO:0000269|PubMed:19919181,
CC       ECO:0000269|PubMed:23880345, ECO:0000269|PubMed:26711270,
CC       ECO:0000269|PubMed:33941617, ECO:0000305|PubMed:24722212,
CC       ECO:0000305|PubMed:9928932}.
CC   -!- SUBUNIT: Interacts with TP53, MDM2, TXNIP (PubMed:16849563,
CC       PubMed:23880345). Interacts (phosphorylated) with PIH1D1. Interacts
CC       with RUVBL1 mediating the PIH1D1-independent association with the R2TP
CC       complex (PubMed:24656813, PubMed:26711270). Interacts with RB1, RBL1
CC       and RBL2; ECD competes with E2F1 for binding to hypophospshorylated RB1
CC       (PubMed:19640839). Interacts with EP300 (PubMed:19919181). Interacts
CC       with DDX39A (PubMed:33941617). {ECO:0000269|PubMed:16849563,
CC       ECO:0000269|PubMed:19640839, ECO:0000269|PubMed:19919181,
CC       ECO:0000269|PubMed:23880345, ECO:0000269|PubMed:24656813,
CC       ECO:0000269|PubMed:26711270, ECO:0000269|PubMed:33941617}.
CC   -!- INTERACTION:
CC       O95905; Q9NWS0: PIH1D1; NbExp=11; IntAct=EBI-2557598, EBI-357318;
CC       O95905; Q6P2Q9: PRPF8; NbExp=6; IntAct=EBI-2557598, EBI-538479;
CC       O95905; Q9Y265: RUVBL1; NbExp=8; IntAct=EBI-2557598, EBI-353675;
CC       O95905; Q9H3M7: TXNIP; NbExp=6; IntAct=EBI-2557598, EBI-1369170;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16849563,
CC       ECO:0000269|PubMed:19919181, ECO:0000269|PubMed:26711270}. Nucleus
CC       {ECO:0000269|PubMed:16849563, ECO:0000269|PubMed:19919181,
CC       ECO:0000269|PubMed:26711270, ECO:0000269|PubMed:33941617}.
CC       Note=Predominantly is located in the cytoplasm.
CC       {ECO:0000269|PubMed:16849563, ECO:0000269|PubMed:19919181,
CC       ECO:0000269|PubMed:26711270}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O95905-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95905-2; Sequence=VSP_045670;
CC       Name=3;
CC         IsoId=O95905-3; Sequence=VSP_045671;
CC   -!- TISSUE SPECIFICITY: Highly expressed in muscle and heart. Over-
CC       expressed in pancreatic and breast cancers.
CC       {ECO:0000269|PubMed:22270930, ECO:0000269|PubMed:22977192}.
CC   -!- PTM: Phosphorylated predominantly by CK2 on two serine-containing
CC       clusters; involved in cell cycle regulation activity.
CC       {ECO:0000269|PubMed:26711270}.
CC   -!- SIMILARITY: Belongs to the ECD family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D88208; BAA75199.1; -; mRNA.
DR   EMBL; AK315711; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK225519; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC016394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000721; AAH00721.1; -; mRNA.
DR   CCDS; CCDS44433.1; -. [O95905-2]
DR   CCDS; CCDS44434.1; -. [O95905-3]
DR   CCDS; CCDS7321.1; -. [O95905-1]
DR   RefSeq; NP_001129224.1; NM_001135752.1. [O95905-3]
DR   RefSeq; NP_001129225.1; NM_001135753.1. [O95905-2]
DR   RefSeq; NP_009196.1; NM_007265.2. [O95905-1]
DR   AlphaFoldDB; O95905; -.
DR   BioGRID; 116450; 134.
DR   IntAct; O95905; 89.
DR   MINT; O95905; -.
DR   STRING; 9606.ENSP00000401566; -.
DR   GlyGen; O95905; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O95905; -.
DR   PhosphoSitePlus; O95905; -.
DR   BioMuta; ECD; -.
DR   jPOST; O95905; -.
DR   MassIVE; O95905; -.
DR   PaxDb; 9606-ENSP00000401566; -.
DR   PeptideAtlas; O95905; -.
DR   ProteomicsDB; 12074; -.
DR   ProteomicsDB; 19095; -.
DR   ProteomicsDB; 51121; -. [O95905-1]
DR   Pumba; O95905; -.
DR   Antibodypedia; 29316; 229 antibodies from 26 providers.
DR   DNASU; 11319; -.
DR   Ensembl; ENST00000372979.9; ENSP00000362070.4; ENSG00000122882.11. [O95905-1]
DR   Ensembl; ENST00000430082.6; ENSP00000401566.1; ENSG00000122882.11. [O95905-3]
DR   Ensembl; ENST00000454759.6; ENSP00000395786.1; ENSG00000122882.11. [O95905-2]
DR   GeneID; 11319; -.
DR   KEGG; hsa:11319; -.
DR   MANE-Select; ENST00000372979.9; ENSP00000362070.4; NM_007265.3; NP_009196.1.
DR   UCSC; uc001jtn.4; human. [O95905-1]
DR   AGR; HGNC:17029; -.
DR   CTD; 11319; -.
DR   DisGeNET; 11319; -.
DR   GeneCards; ECD; -.
DR   HGNC; HGNC:17029; ECD.
DR   HPA; ENSG00000122882; Low tissue specificity.
DR   MIM; 616464; gene.
DR   neXtProt; NX_O95905; -.
DR   OpenTargets; ENSG00000122882; -.
DR   PharmGKB; PA143485450; -.
DR   VEuPathDB; HostDB:ENSG00000122882; -.
DR   eggNOG; KOG2406; Eukaryota.
DR   GeneTree; ENSGT00390000015361; -.
DR   HOGENOM; CLU_006241_2_0_1; -.
DR   InParanoid; O95905; -.
DR   OMA; TKDYIWQ; -.
DR   OrthoDB; 27237at2759; -.
DR   PhylomeDB; O95905; -.
DR   TreeFam; TF324229; -.
DR   PathwayCommons; O95905; -.
DR   SignaLink; O95905; -.
DR   BioGRID-ORCS; 11319; 811 hits in 1165 CRISPR screens.
DR   ChiTaRS; ECD; human.
DR   GeneWiki; ECD_(gene); -.
DR   GenomeRNAi; 11319; -.
DR   Pharos; O95905; Tbio.
DR   PRO; PR:O95905; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; O95905; protein.
DR   Bgee; ENSG00000122882; Expressed in sural nerve and 189 other cell types or tissues.
DR   ExpressionAtlas; O95905; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IDA:UniProtKB.
DR   GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   InterPro; IPR010770; Ecd.
DR   PANTHER; PTHR13060:SF0; PROTEIN ECDYSONELESS HOMOLOG; 1.
DR   PANTHER; PTHR13060; SGT1 PROTEIN HSGT1 SUPPRESSOR OF GCR2; 1.
DR   Pfam; PF07093; SGT1; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Cytoplasm; mRNA processing; mRNA splicing;
KW   Nucleus; Phosphoprotein; Proteomics identification; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..644
FT                   /note="Protein ecdysoneless homolog"
FT                   /id="PRO_0000220844"
FT   REGION          430..449
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          439..644
FT                   /note="Transcription activation"
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   REGION          481..497
FT                   /note="Involved in nuclear export"
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   REGION          496..537
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          502..532
FT                   /note="Acidic region required for transactivation activity"
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   REGION          567..589
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          623..644
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        431..447
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        503..523
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        524..534
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        567..577
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         505
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         262..304
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_045670"
FT   VAR_SEQ         375
FT                   /note="E -> ERLEVQWRDPGLLQAPPPGFTPFICLSLLSTWDN (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045671"
FT   VARIANT         45
FT                   /note="R -> Q (in dbSNP:rs3812619)"
FT                   /id="VAR_051970"
FT   VARIANT         281
FT                   /note="R -> G (in dbSNP:rs151023501)"
FT                   /evidence="ECO:0000269|PubMed:11090341"
FT                   /id="VAR_012191"
FT   VARIANT         452
FT                   /note="E -> Q (in dbSNP:rs3736518)"
FT                   /id="VAR_051971"
FT   VARIANT         501
FT                   /note="N -> S (in dbSNP:rs36152134)"
FT                   /id="VAR_051972"
FT   VARIANT         634
FT                   /note="D -> G (in dbSNP:rs2271904)"
FT                   /id="VAR_051973"
FT   MUTAGEN         481
FT                   /note="I->A: Decreases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         484
FT                   /note="D->F: Decreases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         489
FT                   /note="L->A: Decreases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         503
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-505, A-518, A-572, A-579 and A-584."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         505
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-503, A-518, A-572, A-579 and A-584."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         510
FT                   /note="D->R: Increases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         512
FT                   /note="D->R: Increases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         518
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-503, A-505, A-572, A-579 and A-584."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         520
FT                   /note="D->P: Increases transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:19919181"
FT   MUTAGEN         572
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-503, A-505, A-518, A-579 and A-584."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         579
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-503, A-505, A-518, A-572 and A-584."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         584
FT                   /note="S->A: Greatly impairs in vitro phosphorylation by
FT                   CK2 and impairs cell cycle regulation activity; when
FT                   associated with A-503, A-505, A-518, A-572 and A-579."
FT                   /evidence="ECO:0000269|PubMed:26711270"
FT   MUTAGEN         617
FT                   /note="P->G: Complete loss of interaction with DDX39A."
FT                   /evidence="ECO:0000269|PubMed:33941617"
FT   CONFLICT        28
FT                   /note="S -> P (in Ref. 2; AK225519)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        319
FT                   /note="F -> S (in Ref. 2; AK225519)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        333
FT                   /note="W -> R (in Ref. 2; AK225519)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   644 AA;  72758 MW;  F9B0D2BBFDB38CAF CRC64;
     MEETMKLATM EDTVEYCLFL IPDESRDSDK HKEILQKYIE RIITRFAPML VPYIWQNQPF
     NLKYKPGKGG VPAHMFGVTK FGDNIEDEWF IVYVIKQITK EFPELVARIE DNDGEFLLIE
     AADFLPKWLD PENSTNRVFF CHGELCIIPA PRKSGAESWL PTTPPTIPQA LNIITAHSEK
     ILASESIRAA VNRRIRGYPE KIQASLHRAH CFLPAGIVAV LKQRPRLVAA AVQAFYLRDP
     IDLRACRVFK TFLPETRIMT SVTFTKCLYA QLVQQRFVPD RRSGYRLPPP SDPQYRAHEL
     GMKLAHGFEI LCSKCSPHFS DCKKSLVTAS PLWASFLESL KKNDYFKGLI EGSAQYRERL
     EMAENYFQLS VDWPESSLAM SPGEEILTLL QTIPFDIEDL KKEAANLPPE DDDQWLDLSP
     DQLDQLLQEA VGKKESESVS KEEKEQNYDL TEVSESMKAF ISKVSTHKGA ELPREPSEAP
     ITFDADSFLN YFDKILGPRP NESDSDDLDD EDFECLDSDD DLDFETHEPG EEASLKGTLD
     NLKSYMAQMD QELAHTCISK SFTTRNQVEP VSQTTDNNSD EEDSGTGESV MAPVDVDLNL
     VSNILESYSS QAGLAGPASN LLQSMGVQLP DNTDHRPTSK PTKN
//